Heyuan Biotech announced that the company plans to repurchase shares through centralized bidding transactions to protect the company's value and shareholders' rights. The total repurchase capital is not less than 25 million yuan, no more than 50 million yuan, and the repurchase price is not higher than 9.00 yuan/share. According to the upper limit, it is estimated that 2.777,800 shares to 5.555 million shares will be repurchased, accounting for 0.43%-0.86% of the total share capital. The implementation period for the repurchase is within 3 months from the date of review and approval by the board of directors. The funding source is own funds and/or self-financing. Among them, it has received a repurchase loan commitment of not more than 45 million yuan from the Shanghai branch of Industrial Bank of China. As of the disclosure date of the announcement, the company's directors, supervisors, controlling shareholders, actual controllers and co-actors, and shareholders holding 5% or more of the shares have no plans to reduce their holdings for the next 3 or 6 months.

Heyuan Biotech announced that the company plans to repurchase shares through centralized bidding transactions to protect the company's value and shareholders' rights. The total repurchase capital is not less than 25 million yuan, no more than 50 million yuan, and the repurchase price is not higher than 9.00 yuan/share. According to the upper limit, it is estimated that 2.777,800 shares to 5.555 million shares will be repurchased, accounting for 0.43%-0.86% of the total share capital. The implementation period for the repurchase is within 3 months from the date of review and approval by the board of directors. The source of funding is own funds and/or self-financing. Among them, it has received a repurchase loan commitment of not more than 45 million yuan from the Shanghai branch of Industrial Bank of China. As of the disclosure date of the announcement, the company's directors, supervisors, controlling shareholders, actual controllers and co-actors, and shareholders holding 5% or more of the shares have no plans to reduce their holdings for the next 3 or 6 months.